



CIBC Health Care Conference

**Nicholas L. Teti, Jr.
Chairman & CEO, Isolagen Inc.
November 8, 2006**



Safe Harbor Provision

This presentation includes statements that are “forward-looking statements.” While management has based any forward-looking statements contained in the presentation on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Isolagen’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under the caption “Item 1A. Risk Factors” in Isolagen’s most recent Form 10-K filing, as updated in “Item 1A. Risk Factors” in Isolagen’s most recent Form 10-Q filing. In addition, Isolagen operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Isolagen disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Isolagen’s most recent annual report on Form 10-K, our most recent 10-Q as well as other public filings with the SEC since the filing of Isolagen’s annual report.



Isolagen Incorporated

- The Company has a new beginning, new management, a new strategy and a promising technology.
- The Business will move forward on
 - solid financial management,
 - highest quality/lowest cost manufacturing,
 - marketable science,
 - operational discipline,
 - practical decision making and,
 - transparency.
- The primary vision of the company is to bring novel “premium priced” products to the market in the areas of skin rejuvenation based on solid science.
- A “100 Day Plan” to move the company forward is being implemented



**Progress
Against
“100 Day Plan”**



Progress to Date: 100-Day Plan

- ✓ Developed a Strategic Intent for the Business
- ✓ Gained FDA agreement on Isolagen SPA
 - Initiated Isolagen Pivotal Phase III Study in wrinkles
- ✓ Analyzed, made decision on near term future of UK operations
- ✓ Hired VP of Operations; *Cost of Goods Outlook Improving*
- ✓ Interviewing/pursuing buyers for Switzerland plant
- ✓ 2 shareholder lawsuits dismissed



Progress to Date: 100-Day Plan

- ✓ **Acquired majority ownership in Agera**
- ✓ **Continuing to develop clinical development strategy for the use of the Isolagen Process in burn and acne scars**
- ✓ **Continuing to upgrade US market potential for the Isolagen process across key indications/building five year plan**
- ✓ **Developing plans for dental application**
- ✓ **Evaluating potential of orthopedics**
- ✓ **Hired key consultant for Regulatory Affairs**



Strategic Intent

- **Focus** on a select number of Skin Rejuvenation Areas/partner on others.
- **Advance the Clinical Development** of the Isolagen Process in defined aesthetic/therapeutic areas
- **Streamline & Drive** a High Efficiency and Effective Manufacturing System
- **Grow through in-licensing** and/or acquisition of products and/or small companies
- **Expediently hire** the best people for key positions



Decision on the UK

- Intention to close the UK site-- decision made
- Further financial losses in the UK business not in the Company's best interests.
- Decision not made on the basis of product performance or product quality
- Company made a significant investment in the UK, but
- After a full business and economic analysis, we have determined that the best use of our personnel & financial resources is to focus on the business' strategic opportunities



Cost of Goods Issue

- Extion site currently manufacturing clinical supplies for the “wrinkle” and dental study
- New Operations Leader in place
- Tremendous effort being exerted to study, understand, evaluate & take action how to reduce costs at all points of the Isolagen operations process
- Outlook on competitive commercial cost efficiencies---Improving!
- Third party contract manufacturer evaluated
- Goal is for Extion to be High Quality/Low Cost Manufacturing Center
- Efficiency and Expertise of Manufacturing Personnel will continue to be pursued




isolagen

**Isolagen
Technology**



Isolagen Technology Overview

- **Novel, patented, autologous cell processing system with potential to provide skin rejuvenation**
 - ❑ A persons own collagen-producing cells, or fibroblasts, are extracted, reproduced and then re-introduced by injection
 - ❑ Stimulated living cells multiply
 - ❑ More supple/rejuvenated skin desired outcome
- **Isolagen is not a “fancy” dermal filler**
- **The Potential for Isolagen technology goes beyond aesthetics**
 - ❑ Burn Scars/ Burns
 - ❑ Acne scars
 - ❑ Dental (Papillary Growth)
 - ❑ Orthopedics



isolagen



**Isolagen
Technology:
Aesthetics,
Burn Scars and
Acne Scars**



Strategic Focus— Isolagen Market Potential

Skin Rejuvenation



Aesthetics



**\$75MM - \$250MM
Market Potential**



Burn Scars



**\$125MM - \$750MM
Market Potential**



Acne Scars



**\$40MM - \$200MM
Market Potential**

ISOLAGEN



Phase III Trial Study Design

The New Study

- Study operating under a Special Protocol Assessment (SPA)
- Two identical clinical trials: IT-R-005 and IT-R-006
- Randomized, double-blind, pivotal Phase III trials to evaluate the efficacy and safety of Isolagen(TM) Therapy (IT) against placebo for the treatment of nasolabial skin fold wrinkles
 - Each trial will include 200 patients
 - 100 patients in each trial will receive Isolagen processed living cells
- 12 clinical trial sites
- *Currently enrolling—biopsies coming in—cells being processed!!*



Strategic Focus— Isolagen Market Potential

Skin Rejuvenation



Burn Scars



**\$125MM - \$750MM
Market Potential**

isolagen



Burn Scars: Phase II/III* Trial Draft

- 50 subjects with restrictive burn scars >12 months old
 - Scars with range of motion reduction or pain who would otherwise have plastic surgery to alter scars
 - Subjects to receive 2 treatments of Isolagen therapy 30 days apart
 - Specific endpoints: To be determined but will include improved range of motion, reduction in pain, change in Vancouver scar scale
 - Duration of effectiveness and FDA needs to be addressed
- *Plan: pre-IND meeting to be scheduled to discuss protocol, fast track criteria and clinical plan, projected study start Quarter 1—2007 (subject to FDA non-objection)*

*** If Fast Track Criteria Met**



Strategic Focus— Isolagen Market Potential

Skin Rejuvenation



Acne Scars



**\$40MM - \$200MM
Market Potential**

isolagen



This is an abbreviated review of this clinical study

A Pilot study to assess the efficacy of Isolagen (autologous fibroblasts) treatment in acne scarring

**A.Chu, et al.,
British Journal Of Dermatology, July 06
(155) pg.49**

Discussion

- The results of this study demonstrate that Isolagen treatment can improve atrophic facial acne scarring.
- Patients who responded best were those with soft rolling scars.
- Effect of treatment was less in those with fixed scars and those with small box scars. Results can be optimised by careful patient selection.
- Further larger randomised studies should be done as a follow-up to this study, to confirm the findings of this pilot study. In addition, studies should be done to elucidate the mechanism of action of Isolagen in acne scarring.
- Scarring remains a major complication of acne and the current treatments available for this complication are unsatisfactory.
- Destructive measures such as laser re-surfacing and dermabrasion are not suitable for darker skins and have long down times.
- Fillers only give temporary improvement.
- Acne scarring often demands combinations of treatment and Isolagen should be used in combination with subcision for fixed rolling scars or with Trichloracetic acid CROSS technique for box scars..

isolagen



Strategy around Acne Scars

- Discuss protocol development with Published clinical Researchers
- Develop protocol
- Develop briefing document for FDA
- Call for pre-IND FDA meeting
- File IND
- Initiate Acne scar study in 1st or 2nd quarter



isolagen

**Isolagen
Technology
Dental**



Isolagen-- Application for Papillary Recession

- The single greatest cause of bone and tooth loss in the mouth is periodontal disease.
- Papillary recession, also known as “black triangles,” can be associated with the progression of periodontal disease,
 - *We are not aware of any documented effective treatment for this condition.*
- A majority of the population will experience periodontal disease at some point in their lives.
- Reimbursement for this application is possible but questionable.
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Isolagen Injections for Treatment of Interdental Papillary Insufficiency was conducted (**IT-G-002**)



Isolagen trial IT-G-002

CONCLUSIONS

- Results suggest an increase in papillary growth
- Autologous fibroblasts are safe and may be efficacious for the treatment of papillary recession
- Investigators and subjects Visual Assessment Scale (VAS) assessments of test sites *were superior to placebo at 4 months*
- Objective endpoints *failed to demonstrate statistical significance at 4 months*
- Further studies are underway with more appropriate power and more sensitive measurement techniques

Accepted for publication in the Journal of Periodontology



isolagen

**Agera
Skincare-
Nano-Peptide
Technology
(NPT)TM**




Why Agera?

- Aligns with Skin Rejuvenation strategy
- Keeps Company commercially involved in market
- Should provide a competitive offering to Obagi, SkinCeuticals and SkinMedica
- Access to other Peptide Technologies through Biosyn Corp.
- Excellent product experience in London
- Product Systems concept with “Nano-Peptide TechnologyTM” (NPT) have tested well



Technology Potential

- Nanoemulsion technology offers the potential to deliver active ingredients encapsulated in microscopic particles known as nanosomes to penetrate the stratum corneum and to get to the dermis where new collagen is formed



isolagen



Complete Skincare System

■ AM/PM Daily Systems

- Critical everyday skincare for different skin types

■ Treatment Systems

- Developed to treat specific high demand skincare issues
 - Acne – mild to severe
 - Anti-Aging – fine lines, wrinkles, elasticity
 - Photo-Damaged & Pigmentation

■ Pre/Post Procedures

- Designed to enhance the results of aesthetic procedures
 - Laser
 - Peel
 - Microdermabrasion



Complete Skincare System



Ultra Mild
Cleanser



Ultra Macro Moist



Nanolucent
SPF 25



Prolifersyn 60



Relaxsyn®
Eyelift



isolagen



isolagen

**Critical
Success
Factors**



Critical Success Factors

- Significantly reduce the cost of goods
 - ⚡ Progress being made
- Advance US Phase III aesthetics study---
 - ⚡ Study initiated/patients being enrolled/biopsies being processed
- Intent to Close UK operations
 - ⚡ Decision Made
- Sell the Switzerland site and plant
 - ⚡ Interviewing/pursuing potential buyers
- Finalize plans for burn & acne scar clinical programs
 - ⚡ Plans being developed
 - ⚡ Target --1st or 2nd quarter initiation



Critical Success Factors

- Develop tactical plans on dental program
 - ⚡ In progress
- Evaluate possible application of the Isolagen Process for Orthopedics—
 - ⚡ Research being conducted
- Launch Agera; integrate into Isolagen business
 - ⚡ Launch & Branding Plans for US In Process
 - ⚡ Discussions ongoing for Distribution Agreements in the EU
 - ⚡ Discussions Initiated in Far East for Distribution Options
- Evaluate other potential acquisitions/collaborations
- Evaluate financing alternatives—ongoing
- Continue to evaluate all personnel levels of the business



Why Isolagen?

- New experienced management/expanding expertise
- New business strategy in place and being implemented
- US Phase III “wrinkles” pivotal study initiated
- Innovative technology with a number of potential applications
- Applications, if scientifically proven out, have excellent therapeutic and aesthetics market potential
- External opportunities being evaluated and pursued



**CIBC
Health Care
Conference**

**Nicholas L. Teti, Jr.
Chairman & CEO, Isolagen Inc.
November 8, 2006**